Dr. Wang on Future Research With CAR T-Cell Therapy in MCL

Video

Michael Wang, MD, discusses the importance of additional CAR T-cell therapy research in mantle cell lymphoma.

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the importance of additional CAR T-cell therapy research in mantle cell lymphoma (MCL). 

CAR T-cell therapy is a new ​therapeutic modality in MCL, so additional research is needed, says Wang.

In the phase 2 ZUMA-2 trial, it was discovered that certain cytokines are associated with efficacy and toxicity​, explains Wang. Moreover, future research efforts should aim to develop new measures that could enhance efficacy and minimize​ toxicity in these patients. 

As the ZUMA-2 trial was relatively small, larger studies are necessary to obtain further insight on​ the utility of minimal residual disease, as well as cytokine ​profiling, Wang concludes.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.